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Abstract
Background: The prognostic value of lactate dehydrogenase levels in the prognosis of colorectal cancer patients
has been assessed for years, although the results remain controversial and heterogeneous. Thus, we
comprehensively reviewed the evidence from studies that evaluated lactate dehydrogenase levels in colorectal
cancer patients to determine their effect.
Methods: The following databases were searched in September 2014 to identify studies that evaluated the
prognostic value of lactate dehydrogenase levels in colorectal cancer: PubMed, EMBASE, and the Cochrane Central
Register of Controlled Trials. We extracted hazard ratios (HRs) and the associated 95 % confidence intervals (CIs)
from the identified studies, and performed random-effects model meta-analyses on the overall survival (OS) and
progression-free survival (PFS). Thirty-two studies with a cumulative sample size of 8,261 patients were included in
our analysis.
Results: Our meta-analyses revealed that high levels of lactate dehydrogenase were associated with poor OS
(HR, 1.75; 95 % CI, 1.52–2.02) in colorectal cancer patients. However, this effect was not obvious in the OS of non-
metastatic colorectal cancer patients (HR, 1.21; 95 % CI, 0.79–1.86). The prognostic value of lactate dehydrogenase
levels on PFS was also not confirmed (HR, 1.36; 95 % CI, 0.98–1.87). Subgroup analyses revealed that the prognostic
significance of lactate dehydrogenase was independent of study location, patient age, number of patients,
metastasis, chemotherapy with anti-angiogenesis drugs, study type, or risk of bias.
Conclusions: Our results indicate that high lactate dehydrogenase levels are associated with poor OS among
colorectal cancer patients, although these levels are not significant predictors of PFS.
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Background
Colorectal cancer (CRC) represents the third most com-
mon malignancy throughout the world [1]. The prognosis
for late stage CRC is extremely poor, and survival is often
measured in months once metastases are present. More-
over, despite the fact that advances in modern systemic
therapies for CRC have resulted in improved survival,
the failure rate in the adjuvant setting is 30 % for
high risk Stage II and Stage III patients, and the over-
all response rate is only 60 % for patients with Stage
IV CRC [2, 3]. Therefore, it is necessary to discover
biomarkers that can identify patients that are at-risk
for disease recurrence and survival.
Cancer cells rely heavily on aerobic glycolysis to support
their growth, a process that is known as the Warburg
effect [4, 5]. Lactate dehydrogenase plays an important
role in this process by mediating the conversion of pyru-
vate and lactate, and this enzyme is an emerging antican-
cer target [6]. In addition, elevated lactate dehydrogenase
levels are consistently reported as a prognostic factor for
poor survival among several cancer groups [7]. The au-
thors conducted a prospective study, including various
cancer types (liver, lung, bone, brain etc.), symptoms, signs
and other serological variables, to evaluate LDH’s value as
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a predictor of survival time in terminal cancer patients.
Their results demonstrated that serum LDH level was
significantly associated with survival time (HR = 2.087,
P = 0.002) in patients with terminal cancer [7]. Although
a large number of studies have been performed among pa-
tients with CRC, the prognostic value of lactate dehydro-
genase levels among CRC patients remains controversial.
Thus, we conducted this meta-analysis to evaluate the
prognostic value of lactate dehydrogenase levels among
CRC patients.
Methods
Search strategy and selection criteria
The following databases were searched in September
2014: PubMed, EMBASE, and the Cochrane Central
Register of Controlled Trials. In addition, we examined
the reference lists of relevant articles and review articles.
No language restrictions or time limits were applied
to the initial search. Search strategies, databases, and
date ranges are provided in the supplemental material
(Additional file 1). Eligibility criteria for inclusion in
this meta-analysis were: [1] the study evaluated the
correlation between lactate dehydrogenase levels and
survival among CRC patients, [2] the study provided
sufficient information for the estimation of hazard ratios
(HRs) and their 95 % confidence intervals (CIs), and [3]
the study was published in English, German, or French.
Two reviewers (L.G.H. and W.Z.) independently screened
the identified abstracts for eligibility, and disagreements
were resolved by discussion. When multiple publications
reported identical or overlapping patient cohorts (e.g.,
same authors, institutions), only the most informative
study was included in the analysis.
Data extraction
Two investigators (L.G.H. and W.Z.) independently
extracted the following data from the eligible articles:
first author, year of publication, study location, sample
size, patient age, site of disease, stage of disease, Lactate
dehydrogenase cut-off value, use of adjuvant chemo-
therapy, prognostic outcomes, use of multivariate
models, and study type.
Study quality assessment
The quality of the included studies was assessed using
the modified risk of bias tool that is recommended by
the Cochrane Collaboration, as previously described
[8, 9]. Briefly, the criteria in Additional file 2 were used to
assess the risk of bias of included studies. Each question is
answered with “Yes” (indicating low risk of bias),
“No” (indicating high risk of bias), and “Unclear” (indicat-
ing unclear or unknown risk of bias). The summary as-
sessment of the risk of bias for the individual studies was
carried out as follows: 1. Low risk of bias: Low risk of bias
for all domains. 2.Unclear risk of bias: Unclear risk of bias
for one or more domains. 3.High risk of bias: High risk of
bias for one or more domains.
Statistical analyses
The prognostic value of lactate dehydrogenase levels for
survival was measured using HRs. If an HR and the
associated standard error or CI was not reported, we
approximated the HR using the statistical data that
was provided in the article (e.g., individual patient data or
survival plots) [10, 11]. The extracted HRs were pooled
using a fixed-effects model (weighted with inverse
variance) or a random-effects model [12]. Our method
consisted of using the fixed-effects model with an assump-
tion of homogeneity in the individual HRs. Heterogeneity
between studies was assessed using the χ2 and I2 statistics.
If the assumption of homogeneity was rejected, the
random-effects model was used [13].
HR >1 indicated a worsened prognosis in the high lactate
dehydrogenase group, and a minimum of 3 studies was re-
quired to perform the meta-analyses. Sensitivity analysis
was also conducted using sequential omission of individual
studies to evaluate the stability of the results. Funnel plot
analyses were used to evaluate publication bias [14]. All
analyses were performed using STATA version 10.0, and a
p-value <0.05 was considered statistically significant.
Results
Baseline study characteristics
We identified 32 eligible studies with a cumulative sam-
ple size of 8,261 patients (Fig. 1) [15–47]. The median
study sample size was 157 patients (range, 31–855 pa-
tients), and all eligible studies were published between
1988 and 2014 (Table 1). Thirteen studies were excluded
owing to the inclusion of a patient cohort that was also
used in the other selected studies (studies that were ex-
cluded and included were [24, 48–59]). The extracted
variables from the included studies are summarized in
Table 1 (Abbreviations: FOLFOX, infusional fluorouracil,
leucovorin, and oxaliplatin; FU, fluorouracil; IHC, immu-
nohistochemistry; RCT, randomized controlled trial; NR,
not reported; RMCS, retrospective multicenter cohort
study; PSCS, prospective single-center cohort study;
RSCS, retrospective single-center cohort study).
Among the 32 studies that used serum lactate de-
hydrogenase levels to investigate their influence on
patient prognosis, 2 studies [29, 30] used an immu-
nohistochemistry method, and 1 study [30] used serum
levels and immunohistochemistry methods. Twelve stud-
ies were graded with a low risk of bias (Additional file 2).
Our analysis of lactate dehydrogenase levels as a prognos-
tic factor was confirmed by the multivariate analysis in 19
of the included studies [16, 17, 19–23, 25, 27, 28, 30, 32,
34, 35, 38, 40–43]. An HR for overall survival (OS) and
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progression-free survival (PFS) was extracted from 27 and
8 studies, respectively. Funnel plot analyses did not reveal
a significant publication bias regarding the analyzed out-
comes (Additional file 3: Figure S1). However, the funnel
plot B (PFS) does not allow to exclude a publication bias,
because of limited number of studies.
The prognostic value of lactate dehydrogenase levels
Pooled analysis of OS in all studies using the random ef-
fects model revealed a significant prognostic value for
lactate dehydrogenase levels in CRC patients (HR, 1.75;
95 % CI, 1.52–2.02; n = 27; I2 = 66.5 %; Fig. 2a). Sensitiv-
ity analyses revealed that heterogeneity was not caused
by any one study. However, our meta-analyses using the
random effects model did not confirm the prognostic
value for lactate dehydrogenase levels in predicting PFS
(HR, 1.36; 95 % CI, 0.98–1.87; n = 8; I2 = 87 %; Fig. 2b),
and we observed a significant degree of heterogeneity.
This heterogeneity could not be reduced substantially by
the exclusion of any one study.
Subgroup analyses
Despite the limited number of included studies, the sub-
group analyses of lactate dehydrogenase levels and sur-
vival were performed to thoroughly explore the results.
We performed meta-regression and subgroup analysis of
lactate dehydrogenase levels on OS according to study
location, patient age, number of patients, metastasis,
chemotherapy with anti-angiogenesis drugs, study type,
and risk of bias. The results revealed that none of the
investigated factors had a significant association with the
heterogeneity (Table 2). However, subgroup analysis in-
dicated a significant relation between high lactate de-
hydrogenase levels and reduced OS among metastatic
CRC patients (HR, 1.96; 95 % CI, 1.61–2.37), although
this effect was not significant among non-metastatic pa-
tients (HR, 1.21; 95 % CI, 0.79–1.86; Table 2). The effect
of LDH on OS among different cutoffs for LDH is also
shown in Table 2. The HRs were 1.93 (95 % CI 1.50 to
2.49) for LDH cutoff >300U/L, 1.84(95 % CI 1.08 to
3.13) for LDH cutoff 250 to 300U/L and 1.44 (95 % CI
0.94 to 2.21) for LDH cutoff <250U/L. There was no sta-
tistically significant heterogeneity between the different
cutoffs for LDH (P for subgroup difference = 0.309). Our
results suggest that relation between high lactate de-
hydrogenase levels and reduced OS among metastatic
CRC patients disappears if the LDH cutoff value less
than 250U/L (HR, 1.44; 95 % CI 0.94 to 2.21).
Subgroup analysis of the other factors did not alter the
significant prognostic value of lactate dehydrogenase
levels in predicting OS.
We also performed meta-regression and subgroup ana-
lysis of lactate dehydrogenase levels and PFS. Owing to the
limited number of included studies, only study location,
number of patients, chemotherapy with anti-angiogenesis
drugs, and risk of bias were explored. The results revealed
that none of the investigated factors had a significant asso-
ciation with the heterogeneity (Table 3). Moreover, sub-
group analysis revealed no relationship between lactate
dehydrogenase levels and PFS among CRC patients.
Fig. 1 Flow chart for the study selection
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Table 1 Baseline characteristics of included studies
Sample size Age LDH
First author Year Country Total Colon Rectum Median Range Tumor stage Cutoff Detection
method
Adjuvant chemotherapy Suvival analysis Outcome
report
Agrawal 2013 USA 146 NR NR NR <=50 IV 200U/L serum NR Univariate OS
Alonso-Espinaco 2014 Spanish 157 NR NR NR 28–82 mCRC NR serum FOLFOX/XELOX Univariate Multivariate OS PFS
Asmis 2011 Canada 544 NR NR NR NR NR NR serum Cetuximab-based Univariate Multivariate OS
Caputo 2014 Italy 96 88 6 NR 18–80 T2T3T4/M0 248U/L serum NO Univariate OS PFS
Cetin 2012 Turkey 168 NR NR NR NR mCRC NR serum anti-VEGF therapy Multivariate OS
Chibaudel 2011 France 535 349 177 65 29–80 mCRC NR serum Oxaliplatin-Based or Irinotecan-
Based First-Line Chemotherapy
Univariate Multivariate OS
Diouf 2014 France 620 398 211 NR 18–80 mCRC NR serum FOLFOX4 or FOLFOX7 Univariate Multivariate OS
Formica 2013 Italy 31 26 5 69 41–83 mCRC 245U/L serum FOLFORIN + bevacizumab Multivariate PFS
Galizia 2008 Italy 65 53 12 NR 28–84 IV with liver
metastasis
450U/L serum fluorouracil, folinic and acid, and
oxaliplatin/irinotecan
Multivariate OS
Giessen 2013 German 215 136 79 61.8 32–78 mCRC/liver
metastas
250U/L serum FUFURI or mIROX Multivariate OS
Giessen 2014 Italy 249 0 249 64.6 30.6–90.7 I-III 171 serum Chemotherapy/Radiotherapy/
Concomitant chemoradiotherapy
Univariate OS
Hannisdal 1994 Norway 100 0 100 69 33–87 Local regional
relapse ± metastasis
500 serum chemoradiotherapy Multivariate OS
He 2013 China 239 171 68 57 18–83 mCRC 245U/L serum Folfox/Xelox/Folfiri/Xeliri Multivariate OS
Koukourakis 2006 UK 128 78 50 67 41–88 Dukes B,C,D NR IHC NO Univariate OS
Koukourakis 2011 Greece 179 NR NR NR 28–83 mCRC NR serum IHC FOLFOX4 + vatalanib/placebo Univariate Multivariate OS
Lin 2006 USA 66 NR NR 62 30–86 mCRC 618 serum XCEL ± Radiation Univariate OS
Lin 2005 China 45 34 11 32 18–39 Dukes B,C,D 230 serum 5-FU based chemotherapy Multivariate OS
Machida 2008 Japan 103 66 37 62 29–80 mCRC 300 serum LV-modulated 5-FU/irinotecan + 5-FU Univariate OS
Maurel 2007 Spain 120 NR NR 66 33–82 mCRC 450 serum 5-FU + oxaliplatin/irinotecan Multivariate OS
Mekenkam 2012 Netherland 803 538 260 63 27–84 Advanced stage
(curative surgery)













This systematic review and meta-analysis revealed
that high lactate dehydrogenase levels are associated
with poor OS among patients with CRC. However,
this prognostic value was not observed for PFS
among CRC patients.
Despite the number of studies that have been con-
ducted in this field, the prognostic value of lactate
Fig. 2 Meta-analyses of the association between lactate dehydrogenase levels and (a) overall survival or (b) progression-free survival. Squares and
horizontal bars indicate the point estimates (HRs) with 95 % CIs for each individual study. Diamonds indicate the summary estimates for the hazard
ratio. The width of the diamond corresponds to the 95 % CI
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dehydrogenase levels among CRC patients has remained
highly uncertain, given the inconsistent results from the
previous studies. In the present study, pooled analyses of
the available data revealed a significant association be-
tween high lactate dehydrogenase levels and poorer OS.
However, there was insufficient statistical power to de-
tect this association among patients with non-metastatic
disease (Pooled HR1.21, 95 % CI [0.79, 1.86]).
There is recent evidence that the addition of anti-
angiogenesis medication diminishes the impact of lactate
dehydrogenase expression on the prognosis of CRC pa-
tients [30]. Besides, recent research reveals that high
LDH is a significant indicator of bevacizumab-based
chemotherapy-induced response to treatment for previ-
ously untreated metastatic colorectal cancer patients
[60]. However, our meta-analysis did not detect a similar
effect among CRC patients. This discrepancy may be
attributed to the different kinds of anti-angiogenesis
medications that were used in the previous study. Com-
bined with the different dose that was employed for the
anti-angiogenesis medications, there was insufficient
statistical power to detect any differences in the sur-
vival of CRC patients (p = 0.64). However, our data
supports the approach to aggregate results from the
available studies regarding the prognostic significance
of anti-angiogenesis drugs in CRC.
Interestingly, we detected significant heterogeneity
among the studies that were included in this systematic
review. However, sensitivity analysis did not identify the
source of this heterogeneity. We did observe a wide
Table 2 Stratified analysis of pooled hazard ratios of lactate dehydrogenase on overall survival
Pooled HR (95 % CI) Heterogeneity




Asia 4 580 1.66 [1.29, 2.14] 1.82 [1.14, 2.9] 67.9 0.025
Europe 19 5276 1.66 [1.53, 1.80] 1.67 [1.40, 2.0] 69.5 <0.001
Other regions 5 1065 1.85 [1.52, 2.25] 2.07 [1.45, 2.94] 64.1 0.025
Age 0.563
≤ 50 2 191 1.98 [1.33, 2.94] 2.31 [1.04, 5.13] 63.1 0.1
No limitation 22 5623 1.70 [1.57, 1.84] 1.77 [1.51, 2.08] 68.5 <0.001
Number of patients 0.68
≥ 100 22 6428 1.68 [1.56, 1.81] 1.73 [1.49, 2.01] 69 <0.001
< 100 6 439 1.84 [1.66, 2.04] 1.96 [1.11, 3.43] 60.3 0.28
Metastasis 0.059
Yes 16 5044 1.84 [1.66, 2.04] 1.96 [1.61, 2.37] 64.4 <0.001
No 5 883 1.53 [1.29, 1.82] 1.21 [0.79, 1.86] 74.4 0.028
LDH cutoff 0.309
> 300 U/L 7 764 1.93 [1.50, 2.49] 1.98 [1.41, 2.77] 29.1 0.206
250–300 U/L 5 1028 1.61 [1.38, 1.88] 1.84 [1.08, 3.13] 88.6 <0.001




Yes 5 1675 1.75 [1.51, 2.02] 1.78 [1.41, 2.23] 57.3 0.053
No 16 4166 1.60 [1.46, 1.75] 1.65 [1.40, 1.94] 54.8 0.003
Study type 0.863
non-RCTa 22 3683 1.66 [1.51, 2.02] 2.03 [1.31, 3.13] 71.5 <0.001
RCT 5 3238 1.73 [1.54, 1.94] 1.73 [1.54, 1.94] <0.01 0.535
Risk of bias 0.31
High 16 3142 1.52 [1.36, 1.68] 1.63 [1.28, 2.09] 76.5 <0.001
Low 11 3799 1.87 [1.69, 2.07] 1.65 [1.28, 2.12] <0.01 0.655
anon-RCT includes PSCS, RMCS and RSCS groups
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range in the cut-off levels for lactate dehydrogenase;
therefore, additional standardization should be addressed
in the design of future studies, thereby enhancing the
utility of their results. Most of the studies that we in-
cluded focused on metastatic CRC patients, which
could also be a source of bias. In addition, our ap-
proach of extrapolating the HRs from the survival plots
might be another potential source of bias. Although we
extracted the survival rates from survival curve graphs
using Engauge software, this approach did not com-
pletely eliminate inaccuracies during the extraction of
the survival rates. Moreover, the language of publica-
tion may have added additional bias, as the present re-
view was restricted to articles published in English,
German, or French, as other languages were not access-
ible for the readers. This bias could favor positive stud-
ies, which are more frequently published in English, as
negative studies tend to be published in the authors’
native languages.
Conclusions
In conclusion, there is evidence that high lactate de-
hydrogenase levels indicate poor prognosis among CRC
patients. However, subgroup analysis revealed no such
prognostic value among non-metastatic CRC patients.
These findings should encourage efforts to identify sub-
populations with high lactate dehydrogenase levels that
might put metastatic patients at a particular risk of
poor survival.
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